<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17000" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Abacavir</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fernandez</surname>
            <given-names>Jared Vincent B.</given-names>
          </name>
          <aff>Riverside Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Munir</surname>
            <given-names>Ahmed</given-names>
          </name>
          <aff>Creighton University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jared Vincent Fernandez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmed Munir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17000.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This program focuses on the role of abacavir, a nucleoside reverse transcriptase inhibitor, in treating human immunodeficiency virus 1 (HIV-1) infection when combined with other antiretroviral agents. This course&#x000a0;explores the indications, dosing schedules, contraindications, and potential adverse effects&#x000a0;of abacavir use. Antiretroviral therapy is a critical factor in achieving favorable outcomes for HIV patients, and this program places a significant emphasis on the importance of treatment adherence and the prevention of drug resistance.</p>
        <p>This course highlights the crucial role of an interprofessional healthcare team in caring for individuals with HIV. By integrating the expertise and perspectives of various healthcare professionals, this program ensures a comprehensive approach to patient care, ultimately leading to optimal treatment strategies and improved patient outcomes. Participants will gain valuable insights and tools to manage HIV effectively, reduce the risk of drug resistance, and enhance treatment adherence, contributing to the overall success of antiretroviral therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients who&#x000a0;require antiretroviral therapy, including abacavir, for managing HIV-1 based on clinical guidelines and diagnostic criteria.</p></list-item><list-item><p>Implement and integrate abacavir into antiretroviral regimens efficiently, adhering to prescribed dosages and appropriate combinations as per established HIV treatment protocols.</p></list-item><list-item><p>Assess patient responses to abacavir therapy regularly, monitoring treatment adherence, viral load suppression, and potential drug-related complications through laboratory tests and clinical evaluations.</p></list-item><list-item><p>Determine strategies&#x000a0;with other healthcare team members to ensure seamless implementation, monitoring, and optimization of abacavir therapy within the broader context of HIV management.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17000&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17000">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17000.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Abacavir is an FDA-approved drug used to treat HIV-1 infection in conjunction with other antiretroviral drugs. Like other nucleoside reverse-transcriptase inhibitors (NRTIs), abacavir use is typically combined with other HIV medications. Abacavir&#x000a0;is not recommended for use as monotherapy.<xref ref-type="bibr" rid="article-17000.r1">[1]</xref>&#x000a0;Abacavir can be taken by mouth as a tablet or solution, and it is an approved treatment option for patients older than 3 months.<xref ref-type="bibr" rid="article-17000.r2">[2]</xref>&#x000a0;Commonly, abacavir is dispensed with other HIV medications such as abacavir/lamivudine/zidovudine, abacavir/dolutegravir/lamivudine, and abacavir/lamivudine.<xref ref-type="bibr" rid="article-17000.r3">[3]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Abacavir is FDA-approved to treat HIV infection in adults and children older than 3 months.</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA-Approved (Off-Label) Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of HIV infection in pediatric patients younger than 3 months</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17000.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Abacavir&#x000a0;is a nucleoside reverse transcriptase inhibitor, specifically a carbocyclic 2'-deoxyguanosine, also known as a guanosine analog. Taking abacavir with food has not had any clinically relevant effect on exposure to the drug and can be safely ingested&#x000a0;without regard to food.</p>
        <p>The antiviral effect of abacavir is due to its intracellular anabolite, carbovir-triphosphate, which interferes with HIV viral RNA-dependent DNA polymerase (reverse transcriptase), leading to inhibition of viral replication.<xref ref-type="bibr" rid="article-17000.r4">[4]</xref> This intracellular&#x000a0;anabolite&#x000a0;has been shown to have a long elimination half-life of over 20 hours, allowing for once-daily dosing.<xref ref-type="bibr" rid="article-17000.r5">[5]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>
<bold>Absorption</bold>
</p>
        <p>Abacavir is rapidly and extensively absorbed following oral administration (83%). Following twice daily administration of a 300 mg dose, the peak plasma concentration (Cmax) was 3.0 &#x000b1; 0.89 &#x003bc;g/mL, and the area under the curve (AUC) was 6.02 &#x000b1; 1.73 &#x003bc;g*hr/mL.&#x000a0;</p>
        <p>
<bold>Distribution</bold>
</p>
        <p>Abacavir's volume of distribution is&#x000a0;0.86 &#x000b1; 0.15 L/kg following IV administration.&#x000a0;Plasma protein binding is about 50% and has an independent relationship with the plasma concentration of the drug.</p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>Abacavir is hepatically metabolized&#x000a0;by alcohol dehydrogenase and glucuronosyltransferase to a 5&#x02032;-carboxylic acid metabolite and 5&#x02032;-glucuronide metabolite, respectively. These metabolites do not possess any&#x000a0;antiviral activity. Abacavir does not undergo significant metabolism&#x000a0;via the cytochrome P450 enzyme&#x000a0;system.<xref ref-type="bibr" rid="article-17000.r5">[5]</xref></p>
        <p>
<bold>Excretion</bold>
</p>
        <p>Excretion is 82.2% (1.2% unchanged) in urine and 16% in the feces. The drug's half-life is&#x000a0;1.54 &#x000b1; 0.63 hours.</p>
        <p>Singh R. et al conducted a clinical trial with 12 patients (4 men and&#x000a0;8 women) of Japanese ancestry to determine the safety and pharmacokinetics of a treatment combination (abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg) in a single dose tablet after fasting for&#x000a0;8 hours. The researchers collected blood samples more than 72 hours after dosing to determine several pharmacokinetic parameters. The geometric mean maximum plasma concentrations for abacavir, dolutegravir, and lamivudine were 5.22, 4.13, and 3.35 &#x003bc;g/mL, respectively. The time to maximum concentration for abacavir, dolutegravir, and lamivudine were 1.01, 3.50, and 2.98 hours, respectively. The geometric mean area under the concentration-time curve for abacavir, dolutegravir, and lamivudine was 18.2, 71.6, and 16.6 micrograms &#x003bc;g*hr/mL, respectively. The research subjects did not report any adverse drug effects. Dolutegravir was found to have a higher area under the concentration-time curve in this study than in the previously mentioned studies.<xref ref-type="bibr" rid="article-17000.r6">[6]</xref></p>
        <p>The pharmacokinetic parameters for abacavir and lamivudine were similar to previously reported clinical trial data from healthy Japanese and European or African ancestry subjects. Enrolling patients of many different ethnic backgrounds helps to determine any differences in the pharmacokinetics and safety of the studied medications.&#x000a0;Many clinical trials are also conducted with patients of European ancestry.</p>
        <p>Archary M. et al studied the pharmacokinetics of abacavir and lamivudine in severely malnourished children (N = 75) with human immunodeficiency virus from South Africa. The children's ages ranged from 0.1 to 10.8 years and were dosed based on World Health Organization (WHO) weight-band recommendations. The children were randomized to receive treatment with abacavir and lamivudine within 14 days (early) or after nutritional recovery (delayed). Abacavir and lamivudine pharmacokinetic parameters were measured on days 1 and 14. The children received follow-up to week 48.</p>
        <p>Abacavir demonstrated a 2-compartment pharmacokinetic model. The early treatment cohort demonstrated a 31% increase in their bioavailability of abacavir. The apparent clearance (CL/F) of abacavir increased from a mean of 3.33 to 5.86 L/h/7 kg from day 1 to day 14. Lamivudine demonstrated a 1-compartment pharmacokinetic model. Variability in the apparent clearance was best explained by age maturation. Archary M. et al concluded that the WHO weight-band dosing recommendations are appropriate, and the pharmacokinetic variability of abacavir and lamivudine treatment in severely malnourished children did not affect its efficacy.<xref ref-type="bibr" rid="article-17000.r7">[7]</xref></p>
      </sec>
      <sec id="article-17000.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Abacavir is available in 300 mg tablets and as a 20 mg/mL solution.</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Abacavir is administered as 300 mg twice daily or 600 mg once daily.&#x000a0;The drug is also available as part of several co-formulated tablets. These different co-formulations&#x000a0;are part of nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) drug combinations.<xref ref-type="bibr" rid="article-17000.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p>
<bold>Hepatic Impairment</bold>
</p>
        <p>Child-Pugh class A is suggested at 200 mg twice daily. Contraindicated in&#x000a0;Child-Pugh class B or C.<xref ref-type="bibr" rid="article-17000.r5">[5]</xref></p>
        <p>
<bold>Renal Impairment</bold>
</p>
        <p>No dosage adjustments are recommended in patients with renal impairment, and abacavir is well-tolerated in patients who would benefit from NRTI use with renal pathology from other antiretrovirals.<xref ref-type="bibr" rid="article-17000.r9">[9]</xref></p>
        <p>
<bold>Pregnant Women</bold>
</p>
        <p>The benefits outweigh the risks in pregnant patients; there is no known teratogenicity based on human data. Patients should enroll in the Antiretroviral Pregnancy Registry.</p>
        <p>
<bold>Breastfeeding Women</bold>
</p>
        <p>Avoid breastfeeding when using abacavir; the risk of postnatal HIV transmission exists despite maternal HIV treatment. No human data is available to assess abacavir's effect on milk production.</p>
        <p>
<bold>Pediatric Patients</bold>
</p>
        <p>
<bold>Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Age 3 months and older</bold>
<list list-type="bullet"><list-item><p><bold>&#x0003c;20 kg:</bold> 16 mg/kg/d orally (solution) once or divided twice daily. The maximum dose is 600 mg/day.</p></list-item><list-item><p><bold>20 to 24 kg:</bold> 16 mg/kg/d orally (solution) either once or divided twice daily. Alternately, 450 mg orally once daily. The maximum dose is 600 mg/day.&#x000a0;</p></list-item><list-item><p><bold>&#x0003e;25 kg:</bold> 16 mg/kg/d orally (solution) either once or divided twice daily. Alternately, 600 mg orally once daily. The maximum dose is 600 mg/day.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Age &#x0003c;1 month (off-label):</bold>&#x000a0;4&#x000a0;mg/kg/d orally (solution) divided twice daily. The maximum dose is 600 mg/day.</p>
          </list-item>
          <list-item>
            <p><bold>Age&#x000a0;1 to 2 months&#x000a0;(off-label):</bold>&#x000a0;8 mg/kg/d orally (solution) divided twice daily. The maximum dose is 600 mg/day.</p>
          </list-item>
        </list>
        <p>
<bold>Older Patients</bold>
</p>
        <p>Research has not been&#x000a0;performed to date&#x000a0;that demonstrates&#x000a0;<italic toggle="yes">s</italic>pecific problems affecting older patients that would limit the use of&#x000a0;abacavir. However, older&#x000a0;patients may have age-related liver, kidney, or heart problems,&#x000a0;potentially requiring caution and&#x000a0;dose adjustment.</p>
      </sec>
      <sec id="article-17000.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The common toxicities of the NRTI class&#x000a0;include&#x000a0;mitochondrial toxicity, which can present as hepatic steatosis, lipoatrophy, pancreatitis, and peripheral neuropathy.<xref ref-type="bibr" rid="article-17000.r10">[10]</xref> Symptomatic lactic acidosis can also occur, and these patients require monitoring due to an increased risk of mortality.<xref ref-type="bibr" rid="article-17000.r11">[11]</xref> Long-term antiretroviral therapy (ART) patients may experience fat redistribution, also known as lipodystrophy.<xref ref-type="bibr" rid="article-17000.r12">[12]</xref>&#x000a0;Clinicians should avoid abacavir in patients with coronary artery disease and those at increased risk of myocardial infarction due to an increased risk of hyperlipidemia and cardiovascular events.<xref ref-type="bibr" rid="article-17000.r13">[13]</xref><xref ref-type="bibr" rid="article-17000.r14">[14]</xref><xref ref-type="bibr" rid="article-17000.r15">[15]</xref></p>
        <p>
<bold>Drug-Drug Reactions</bold>
</p>
        <p>Abacavir does not affect ethanol pharmacokinetics. However, ethanol consumption can impede abacavir elimination through competition for alcohol dehydrogenase enzymes that metabolize abacavir, leading to increased blood levels and drug exposure.<xref ref-type="bibr" rid="article-17000.r16">[16]</xref>&#x000a0;Abacavir should be discontinued for at least&#x000a0;1 month before starting therapy with betibeglogene autotemcel or elivaldogene autotemcel, as it may interfere with gene transfer into apheresed cells.&#x000a0;Abacavir should be withheld until apheresis is completed. Another medication&#x000a0;to be avoided with abacavir is cladribine. Abacavir oral solution should not be coadministered with a lamivudine oral solution, but tablets or capsule formulations are acceptable.</p>
      </sec>
      <sec id="article-17000.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to abacavir in ART therapy include hypersensitivity to abacavir or any formulation component, moderate to severe hepatic impairment, and patients who&#x000a0;test positive for the HLA-B*5701 allele. This allele is&#x000a0;most commonly found&#x000a0;in&#x000a0;White populations at a frequency of 5% to 8%.<xref ref-type="bibr" rid="article-17000.r17">[17]</xref> Also, in patients with moderate to severe hepatic impairment, Child-Pugh class B or C, abacavir administration is relatively contraindicated due to a lack of safety studies.<xref ref-type="bibr" rid="article-17000.r5">[5]</xref></p>
        <p>Abacavir should also be avoided and is relatively contraindicated in individuals who test positive for HLA-DR7 and HLA-DQ3 alleles because evidence shows that switching abacavir for another NRTI leads to a reduced incidence of hypersensitivity reactions.<xref ref-type="bibr" rid="article-17000.r18">[18]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Severe and potentially fatal hypersensitivity reactions have been&#x000a0;associated with&#x000a0;abacavir; this hypersensitivity is part of a multiorgan clinical syndrome.&#x000a0;Patients&#x000a0;carrying the HLA-B*5701 allele&#x000a0;have a high risk for a hypersensitive reaction to abacavir.&#x000a0;Abacavir should be immediately and permanently discontinued in any patient with a hypersensitivity reaction, irrespective of&#x000a0;HLA-B*5701 allele status.</p>
      </sec>
      <sec id="article-17000.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There is some&#x000a0;potential for drug-induced injury to the body that requires monitoring when administering abacavir to patients with HIV. Patients should receive screening for HLA-B*5701 genotype status before starting therapy&#x000a0;or continuing treatment in patients with unknown HLA-B*5701 status. Patients should have CBC with differential, serum creatinine kinase, CD4 count, HIV RNA plasma concentrations, triglycerides, and serum amylases monitored periodically.<xref ref-type="bibr" rid="article-17000.r17">[17]</xref></p>
        <p>Clinicians should be aware of the risk for acute and late-onset hepatotoxicity and monitor AST and ALT concentrations; LFTs should be taken at baseline and again at 3 to 6 months (3 to 4 months in pediatric patients) or following changes in the regimen.<xref ref-type="bibr" rid="article-17000.r19">[19]</xref> Signs of central fat gain or lipoatrophy should be assessed for fat gain or loss to fine-tune ART therapy.<xref ref-type="bibr" rid="article-17000.r20">[20]</xref></p>
      </sec>
      <sec id="article-17000.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Severe and sometimes fatal hypersensitivity reactions can potentially occur with abacavir. Patients with the HLA-B*5701 allele also carry a higher risk for a hypersensitivity reaction to abacavir; hypersensitivity reactions have occurred in those who do not test positive for the HLA-B*5701 allele. All patients should receive screening for the HLA-B*5701 allele.<xref ref-type="bibr" rid="article-17000.r17">[17]</xref></p>
      </sec>
      <sec id="article-17000.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing abacavir administration to HIV patients requires an interprofessional team of healthcare professionals that includes a nurse, laboratory technologists, pharmacists, social workers, and several physicians in different specialties. After HIV diagnosis, prompt admission into HIV medical and adherence/retention is fundamental to the administration of effective antiretroviral therapy. Adherence to antiretroviral therapy (ART) is one of the top factors of favorable HIV treatment outcomes and is necessary to decrease the occurrence of drug resistance within the patient. Common obstacles to successful ART stem from an absence of social support and alcohol or substance abuse, which prevent patients from having sustained therapy.</p>
        <p>The emphasis on adherence cannot be overstated. Physicians, advanced practice practitioners,&#x000a0;specialists, nurses, and pharmacists must all share in the effort to educate the patient and monitor pharmacotherapy adherence. For example, if the patient is chronically late picking up their prescription, the pharmacist must call the physician's office and share this information with the nurse or prescriber. The pharmacist is also responsible for medication reconciliation and verifying dosing parameters. On follow-up visits, the nurse must verify adherence and should do so by asking open-ended questions that encourage the patient to reveal familiarity with their regimen. Failure to take the drugs in ART correctly can result in therapeutic failure for the entire drug class, as the virus can obtain adaptive drug resistance; any ART requires open, interprofessional team communication to ensure the best chance for therapeutic success.&#x000a0;</p>
        <p>
<bold>Recommendations for Increasing Successful Outcomes in Antiretroviral Therapy&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initiation of highly active antiretroviral therapy (HAART) with a high degree of adherence, defined as greater than 95% refills and plasma drug concentrations above the therapeutic&#x000a0;steady-state&#x000a0;concentration,&#x000a0;is&#x000a0;associated with low levels of antiretroviral resistance.<xref ref-type="bibr" rid="article-17000.r21">[21]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Individual-level&#x000a0;monitoring of entry and retention is a strong recommendation for all people diagnosed with HIV.<xref ref-type="bibr" rid="article-17000.r22">[22]</xref><xref ref-type="bibr" rid="article-17000.r23">[23]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Systematic retention monitoring in HIV care is also strongly recommended for all HIV patients.<xref ref-type="bibr" rid="article-17000.r24">[24]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Strengths-based case management from trained social workers increases entry to HIV medical care.<xref ref-type="bibr" rid="article-17000.r25">[25]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Self-report adherence should be obtained routinely in all HIV patients.<xref ref-type="bibr" rid="article-17000.r26">[26]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Regimens of similar efficacy and tolerability,&#x000a0;once-daily&#x000a0;regimens&#x000a0;are recommended in&#x000a0;treatment-na&#x000ef;ve patients starting ART and experienced patients receiving poorly tolerated/complex regimens.<xref ref-type="bibr" rid="article-17000.r26">[26]</xref><xref ref-type="bibr" rid="article-17000.r27">[27]</xref><xref ref-type="bibr" rid="article-17000.r28">[28]</xref><xref ref-type="bibr" rid="article-17000.r29">[29]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Reminders and the use of communication technologies with an interactive component&#x000a0;are recommended to increase adherence <xref ref-type="bibr" rid="article-17000.r30">[30]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Combining education and counseling using specific adherence-related tools is recommended for all patients with HIV.<xref ref-type="bibr" rid="article-17000.r31">[31]</xref><xref ref-type="bibr" rid="article-17000.r32">[32]</xref><xref ref-type="bibr" rid="article-17000.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Directly administered ART (DART) is the recommended course of action in individuals with substance use disorders.<xref ref-type="bibr" rid="article-17000.r34">[34]</xref><xref ref-type="bibr" rid="article-17000.r35">[35]</xref><xref ref-type="bibr" rid="article-17000.r36">[36]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cognitive-behavioral therapy is recommended in patients with depression to improve adherence.<xref ref-type="bibr" rid="article-17000.r37">[37]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17000.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17000&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17000">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17000/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17000">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17000.s11">
        <title>References</title>
        <ref id="article-17000.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Comparative study of antiretroviral drug regimens and drug-drug interactions between younger and older HIV-infected patients at a tertiary care teaching hospital in South Korea.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>2229</fpage>
            <page-range>2229-2241</page-range>
            <pub-id pub-id-type="pmid">30519031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katlama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ingrand</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Loveday</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clumeck</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mallolas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Staszewski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McDade</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.</article-title>
            <source>JAMA</source>
            <year>1996</year>
            <month>Jul</month>
            <day>10</day>
            <volume>276</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-25</page-range>
            <pub-id pub-id-type="pmid">8656503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greig</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Deeks</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.</article-title>
            <source>Drugs</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>503</fpage>
            <page-range>503-14</page-range>
            <pub-id pub-id-type="pmid">25698454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Kakuda</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Kawle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <article-title>Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.</article-title>
            <source>AIDS</source>
            <year>2003</year>
            <month>Oct</month>
            <day>17</day>
            <volume>17</volume>
            <issue>15</issue>
            <fpage>2159</fpage>
            <page-range>2159-68</page-range>
            <pub-id pub-id-type="pmid">14523272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuen</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pakes</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>A review of the pharmacokinetics of abacavir.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2008</year>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>351</fpage>
            <page-range>351-71</page-range>
            <pub-id pub-id-type="pmid">18479171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Adkison</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wolstenholme</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hopking</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wynne</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.</article-title>
            <source>Clin Pharmacol Drug Dev</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>985</fpage>
            <page-range>985-993</page-range>
            <pub-id pub-id-type="pmid">34265164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Archary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mcllleron</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bobat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>LaRussa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sibaya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hennig</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>85</volume>
            <issue>9</issue>
            <fpage>2066</fpage>
            <page-range>2066-2075</page-range>
            <pub-id pub-id-type="pmid">31141195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saag</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Landovitz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Mugavero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sax</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Del Rio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eron</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>F&#x000e4;tkenheuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nthard</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Volberding</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Jul</month>
            <day>24</day>
            <volume>320</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-396</page-range>
            <pub-id pub-id-type="pmid">30043070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Postorino</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Quiros-Roldan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maggiolo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Di Giambenedetto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ladisa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lapadula</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lorenzotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sighinolfi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Castelnuovo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Di Pietro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gotti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mazzini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Torti</surname>
                <given-names>C</given-names>
              </name>
              <collab>MASTER Study Group</collab>
            </person-group>
            <article-title>Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function.</article-title>
            <source>Open AIDS J</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>136</fpage>
            <page-range>136-43</page-range>
            <pub-id pub-id-type="pmid">27563366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boubaker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Flepp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sudre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Furrer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haensel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hirschel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Boggian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chave</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bernasconi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Egger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Opravil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rickenbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Francioli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Telenti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2001</year>
            <month>Dec</month>
            <day>01</day>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>1931</fpage>
            <page-range>1931-7</page-range>
            <pub-id pub-id-type="pmid">11692306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coghlan</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sommadossi</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Jhala</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Many</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.</article-title>
            <source>Clin Infect Dis</source>
            <year>2001</year>
            <month>Dec</month>
            <day>01</day>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>1914</fpage>
            <page-range>1914-21</page-range>
            <pub-id pub-id-type="pmid">11692304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carr</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management.</article-title>
            <source>AIDS</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>17 Suppl 1</volume>
            <fpage>S141</fpage>
            <page-range>S141-8</page-range>
            <pub-id pub-id-type="pmid">12870540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <collab>Strategies for Management of Anti-Retroviral Therapy/INSIGHT</collab>
            <collab>DAD Study Groups</collab>
            <article-title>Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.</article-title>
            <source>AIDS</source>
            <year>2008</year>
            <month>Sep</month>
            <day>12</day>
            <volume>22</volume>
            <issue>14</issue>
            <fpage>F17</fpage>
            <page-range>F17-24</page-range>
            <pub-id pub-id-type="pmid">18753925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>D:A:D Study Group</collab>
              <name>
                <surname>Sabin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Worm</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reiss</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>El-Sadr</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dabis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Wit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Arminio Monforte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Friis-M&#x000f8;ller</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pradier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Apr</month>
            <day>26</day>
            <volume>371</volume>
            <issue>9622</issue>
            <fpage>1417</fpage>
            <page-range>1417-26</page-range>
            <pub-id pub-id-type="pmid">18387667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcus</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Neugebauer</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Leyden</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Quesenberry</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Towner</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Horberg</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2016</year>
            <month>Apr</month>
            <day>01</day>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>413</fpage>
            <page-range>413-9</page-range>
            <pub-id pub-id-type="pmid">26536316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Balesano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation.</article-title>
            <source>AAPS J</source>
            <year>2021</year>
            <month>Jan</month>
            <day>07</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <pub-id pub-id-type="pmid">33415501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mallal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>4</issue>
            <fpage>591</fpage>
            <page-range>591-3</page-range>
            <pub-id pub-id-type="pmid">17317695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mallal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Masel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sayer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Castley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mamotte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>FT</given-names>
              </name>
            </person-group>
            <article-title>Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.</article-title>
            <source>Lancet</source>
            <year>2002</year>
            <month>Mar</month>
            <day>02</day>
            <volume>359</volume>
            <issue>9308</issue>
            <fpage>727</fpage>
            <page-range>727-32</page-range>
            <pub-id pub-id-type="pmid">11888582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christensen</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roxby</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Abacavir/Dolutegravir/Lamivudine (Triumeq)-Induced Liver Toxicity in a Human Immunodeficiency Virus-Infected Patient.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2017</year>
            <season>Summer</season>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>ofx122</fpage>
            <pub-id pub-id-type="pmid">28748198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Waal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maartens</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>e63623</fpage>
            <pub-id pub-id-type="pmid">23723990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrigan</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wynhoven</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brumme</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Brumme</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Montaner</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.</article-title>
            <source>J Infect Dis</source>
            <year>2005</year>
            <month>Feb</month>
            <day>01</day>
            <volume>191</volume>
            <issue>3</issue>
            <fpage>339</fpage>
            <page-range>339-47</page-range>
            <pub-id pub-id-type="pmid">15633092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>McCauley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gamble</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hosseinipour</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kumarasamy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hakim</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Kumwenda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grinsztejn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pilotto</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Godbole</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Mehendale</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chariyalertsak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Eshleman</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Piwowar-Manning</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Makhema</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>de Bruyn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sanne</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Eron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gallant</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Havlir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Swindells</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ribaudo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Elharrar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taha</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Nielsen-Saines</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Celentano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Essex</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>TR</given-names>
              </name>
              <collab>HPTN 052 Study Team</collab>
            </person-group>
            <article-title>Prevention of HIV-1 infection with early antiretroviral therapy.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Aug</month>
            <day>11</day>
            <volume>365</volume>
            <issue>6</issue>
            <fpage>493</fpage>
            <page-range>493-505</page-range>
            <pub-id pub-id-type="pmid">21767103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metsch</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Pereyra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Messinger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Del Rio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Strathdee</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Anderson-Mahoney</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rudy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>L</given-names>
              </name>
              <collab>Antiretroviral Treatment and Access Study (ARTAS) Study Group</collab>
            </person-group>
            <article-title>HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care.</article-title>
            <source>Clin Infect Dis</source>
            <year>2008</year>
            <month>Aug</month>
            <day>15</day>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-84</page-range>
            <pub-id pub-id-type="pmid">18624629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Youmans</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Duffus</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>The impact of retention in early HIV medical care on viro-immunological parameters and survival: a statewide study.</article-title>
            <source>AIDS Res Hum Retroviruses</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>751</fpage>
            <page-range>751-8</page-range>
            <pub-id pub-id-type="pmid">21142607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gardner</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Metsch</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Anderson-Mahoney</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Loughlin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>del Rio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Strathdee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sansom</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Holmberg</surname>
                <given-names>SD</given-names>
              </name>
              <collab>Antiretroviral Treatment and Access Study Study Group</collab>
            </person-group>
            <article-title>Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care.</article-title>
            <source>AIDS</source>
            <year>2005</year>
            <month>Mar</month>
            <day>04</day>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-31</page-range>
            <pub-id pub-id-type="pmid">15750396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deschamps</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>De Geest</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vandamme</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bobbaers</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Peetermans</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Van Wijngaerden</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards.</article-title>
            <source>AIDS Patient Care STDS</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>735</fpage>
            <page-range>735-43</page-range>
            <pub-id pub-id-type="pmid">18754705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Podsadecki</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wilkin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Domingo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hairrell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rode</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.</article-title>
            <source>AIDS Res Hum Retroviruses</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>12</issue>
            <fpage>1505</fpage>
            <page-range>1505-14</page-range>
            <pub-id pub-id-type="pmid">18160008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyle</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Jayaweera</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maa</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Seekins</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression.</article-title>
            <source>HIV Clin Trials</source>
            <year>2008</year>
            <season>May-Jun</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>164</fpage>
            <page-range>164-76</page-range>
            <pub-id pub-id-type="pmid">18547903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dejesus</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morales-Ramirez</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Ebrahimi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maa</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ecker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McColl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seekins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Farajallah</surname>
                <given-names>A</given-names>
              </name>
              <collab>AI266073 Study Group</collab>
            </person-group>
            <article-title>Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2009</year>
            <month>Jun</month>
            <day>01</day>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-74</page-range>
            <pub-id pub-id-type="pmid">19357529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lester</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Ritvo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kariri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karanja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Habyarimana</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sadatsafavi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Najafzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Estambale</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ngugi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Thabane</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gelmon</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Kimani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ackers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plummer</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Nov</month>
            <day>27</day>
            <volume>376</volume>
            <issue>9755</issue>
            <fpage>1838</fpage>
            <page-range>1838-45</page-range>
            <pub-id pub-id-type="pmid">21071074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannheimer</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Morse</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Matts</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Child</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schmetter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Friedland</surname>
                <given-names>GH</given-names>
              </name>
              <collab>Terry Beirn Community Programs for Clinical Research on AIDS</collab>
            </person-group>
            <article-title>Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2006</year>
            <month>Dec</month>
            <day>01</day>
            <volume>43 Suppl 1</volume>
            <fpage>S41</fpage>
            <page-range>S41-7</page-range>
            <pub-id pub-id-type="pmid">17091022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Bruin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hospers</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>van Breukelen</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kok</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Koevoets</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial.</article-title>
            <source>Health Psychol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>421</fpage>
            <page-range>421-8</page-range>
            <pub-id pub-id-type="pmid">20658830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabin</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>DeSilva</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hamer</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Using electronic drug monitor feedback to improve adherence to antiretroviral therapy among HIV-positive patients in China.</article-title>
            <source>AIDS Behav</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>580</fpage>
            <page-range>580-9</page-range>
            <pub-id pub-id-type="pmid">19771504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Altice</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Maru</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Springer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Friedland</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.</article-title>
            <source>Clin Infect Dis</source>
            <year>2007</year>
            <month>Sep</month>
            <day>15</day>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>770</fpage>
            <page-range>770-8</page-range>
            <pub-id pub-id-type="pmid">17712763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macalino</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Mitty</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bazerman</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Delong</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Loewenthal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Caliendo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Flanigan</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <article-title>A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users.</article-title>
            <source>AIDS</source>
            <year>2007</year>
            <month>Jul</month>
            <day>11</day>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1473</fpage>
            <page-range>1473-7</page-range>
            <pub-id pub-id-type="pmid">17589194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maru</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Walton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Springer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Altice</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2009</year>
            <month>Feb</month>
            <day>01</day>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-81</page-range>
            <pub-id pub-id-type="pmid">19131891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17000.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safren</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>O'Cleirigh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Raminani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals.</article-title>
            <source>Health Psychol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">19210012</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
